Umeå University's logo

umu.sePublications
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 21) Show all publications
Danskog, K., Petersen, F., Frängsmyr, L., Gonzalez, G., Becker, M., Lenman, A. & Arnberg, N. (2025). CD46 is a cellular receptor for species D human adenovirus. mBio, 16(11), Article ID e0158725.
Open this publication in new window or tab >>CD46 is a cellular receptor for species D human adenovirus
Show others...
2025 (English)In: mBio, ISSN 2161-2129, E-ISSN 2150-7511, Vol. 16, no 11, article id e0158725Article in journal (Refereed) Published
Abstract [en]

Human adenovirus species D (HAdV-D) contains two-thirds of all known HAdV types (116 in total) and is important as a vector in clinical applications. However, the broad tropism exhibited by several HAdV-D types poses challenges for their use as targeted gene delivery vectors. Since adenoviral tropism is largely governed by receptor usage, we aimed to determine the relative importance of known adenovirus receptors in mediating infection by different HAdV-D types. Here, we generated A549 single-cell CRISPR/Cas9 knockout clones of desmoglein 2 (DSG2), CD46, the coxsackievirus and adenovirus receptor (CAR), and cytidine monophosphate N-acetylneuraminic acid synthetase (CMAS; needed for biosynthesis of sialic acid-containing glycans), and assessed their relative importance for infection by 18 different HAdV-D types. We show that CD46 is the most important receptor for a majority of species D HAdVs. Minor changes in infection levels were noted with A549-ΔCAR and A549-ΔDSG2 cells, whereas A549-ΔCMAS cells displayed an increased susceptibility to infection. We proceed to show that HAdV-D types require CD46 for efficient attachment to A549 cells, and surface plasmon resonance analysis demonstrates that their hexon proteins bind CD46 in an avidity-dependent manner. Strategies to retarget HAdV-D vectors should thus consider hexon-CD46 interactions as a critical determinant of tropism, as CD46 is broadly expressed in vivo. These results increase our understanding of adenovirus-host interactions and will guide the development and targeting of vectors based on HAdV-D types. IMPORTANCE: Several human adenovirus species D (HAdV-D) types are currently used, or under development, as viral vectors for vaccines and gene delivery. However, the unusually broad tropism observed in many HAdV-D types limits their specificity and effectiveness as targeted vectors. Since tropism is largely governed by receptor usage, and previous studies have reported conflicting findings on receptor preferences within this species, clarifying receptor usage is essential. In this study, we systematically investigated receptor usage in 18 different HAdV-D types and identified CD46 as the primary receptor. Since CD46 is widely expressed across human tissues, our findings explain the broad cellular tropism of these viruses and provide valuable insight for the rational design and refinement of HAdV-D-based vectors.

Place, publisher, year, edition, pages
American Society for Microbiology, 2025
Keywords
adenovirus, CD46, receptor-ligand interaction, vector biology, virus-host interactions
National Category
Microbiology in the Medical Area Medical Biotechnology (Focus on Cell Biology, (incl. Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:umu:diva-246785 (URN)10.1128/mbio.01587-25 (DOI)001575516100001 ()40980888 (PubMedID)2-s2.0-105021474222 (Scopus ID)
Funder
Swedish Research Council, 2023-01831Swedish Research Council, 2019-01472Swedish Cancer Society, 22 2005 PjSwedish Cancer Society, CAN 2018/771EU, Horizon Europe, 101098647
Available from: 2025-11-26 Created: 2025-11-26 Last updated: 2025-11-26Bibliographically approved
Danskog, K., Mistry, N., Årdahl, C., Durbeej, M., Forsell, M. N. E., Lenman, A. & Arnberg, N. (2025). Lactoferricin enables adenovirus infection of human skeletal muscle cells. NPJ Viruses, 3(1), Article ID 62.
Open this publication in new window or tab >>Lactoferricin enables adenovirus infection of human skeletal muscle cells
Show others...
2025 (English)In: NPJ Viruses, E-ISSN 2948-1767, Vol. 3, no 1, article id 62Article in journal (Refereed) Published
Abstract [en]

Although adenoviruses (AdVs) possess advantageous features as vectors, several challenges remain. These include a high prevalence of neutralizing antibodies against certain AdV types and the inability to efficiently transduce CAR-deficient cells and tissues. We showed previously that lactoferricin (Lfcin) enhances CAR-independent HAdV-C5 infection of epithelial and T-cells. Here, we assessed the ability of Lfcin to enable HAdV-C5 infection and transduction of human skeletal muscle cells. Lfcin increases HAdV-C5 infection and transduction of muscle myoblasts and myotubes by 10- to 30-fold. Enhanced infection correlates with increased cell binding, which differs mechanistically from that of coagulation factor X-mediated binding, as it remains unaffected by the removal of heparan sulfate. Additionally, Lfcin reduces the neutralizing effects of serum against HAdV-C5, suggesting it may shield key epitopes. By enabling viral binding to muscle cells and mitigating serum neutralization, Lfcin offers a novel strategy to improve the efficiency and durability of HAdV-C5-based gene delivery systems.

Place, publisher, year, edition, pages
Springer Nature, 2025
National Category
Medical Biotechnology (Focus on Cell Biology, (incl. Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy) Microbiology in the Medical Area
Identifiers
urn:nbn:se:umu:diva-246913 (URN)10.1038/s44298-025-00144-7 (DOI)001578516300001 ()40826223 (PubMedID)2-s2.0-105022271801 (Scopus ID)
Funder
EU, Horizon Europe, 10109864Swedish Research Council, 2023-01831Swedish Research Council, 2019–0147Swedish Cancer Society, 22 2005 PjSwedish Cancer Society, CAN 2018/771
Available from: 2025-11-28 Created: 2025-11-28 Last updated: 2025-11-28Bibliographically approved
Mozūraitis, R., Cirksena, K., Raftari, M., Hajkazemian, M., Mustapha Abiodun, M., Brahimi, J., . . . Emami, S. N. (2025). Zika virus modulates human fibroblasts to enhance transmission success in a controlled lab-setting. Communications Biology, 8(1), Article ID 139.
Open this publication in new window or tab >>Zika virus modulates human fibroblasts to enhance transmission success in a controlled lab-setting
Show others...
2025 (English)In: Communications Biology, E-ISSN 2399-3642, Vol. 8, no 1, article id 139Article in journal (Refereed) Published
Abstract [en]

Transmission of Zika virus (ZIKV) has been reported in 92 countries and the geographical spread of invasive virus-borne vectors has increased in recent years. Arboviruses naturally survive between vertebrate hosts and arthropod vectors. Transmission success requires the mosquito to feed on viraemic hosts. There is little specific understanding of factors that may promote ZIKV transmission-success. Here we show that mosquito host-seeking behaviour is impacted by viral infection of the vertebrae host and may be essential for the effective transmission of arboviruses like ZIKV. Human skin fibroblasts produce a variety of metabolites, and we show that ZIKV immediately alters gene/protein expression patterns in infected-dermal fibroblasts, altering their metabolism to increase the release of mosquito-attractive volatile organic compounds (VOCs), which improves its transmission success. We demonstrate that at the invasion stage, ZIKV differentially altered the emission of VOCs by significantly increasing or decreasing their amounts, while at the transmission stage of the virus, all VOCs are significantly increased. The findings are complemented by an extensive meta-proteome analysis. Overall, we demonstrate a multifaceted role of virus-host interaction and shed light on how arboviruses may influence the behaviour of their vectors as an evolved means of improving transmission-success.

Place, publisher, year, edition, pages
Nature Publishing Group, 2025
National Category
Microbiology in the Medical Area Infectious Medicine
Identifiers
urn:nbn:se:umu:diva-235717 (URN)10.1038/s42003-025-07543-9 (DOI)001410015200001 ()39885287 (PubMedID)2-s2.0-85217623533 (Scopus ID)
Funder
Knut and Alice Wallenberg Foundation
Available from: 2025-02-24 Created: 2025-02-24 Last updated: 2025-02-24Bibliographically approved
Hellman, U., Rosendal, E., Lehrstrand, J., Henriksson, J., Björsell, T., Wennemo, A., . . . Lenman, A. (2024). SARS-CoV-2 infection induces hyaluronan production in vitro and hyaluronan levels in COVID-19 patients relate to morbidity and long-term lung impairment: a prospective cohort study. mBio, 15(10), Article ID e01303-24.
Open this publication in new window or tab >>SARS-CoV-2 infection induces hyaluronan production in vitro and hyaluronan levels in COVID-19 patients relate to morbidity and long-term lung impairment: a prospective cohort study
Show others...
2024 (English)In: mBio, ISSN 2161-2129, E-ISSN 2150-7511, Vol. 15, no 10, article id e01303-24Article in journal (Refereed) Published
Abstract [en]

We previously demonstrated that the lungs of deceased COVID-19 patients were filled with a clear hydrogel consisting of hyaluronan (HA). In this translational study, we investigated the role of HA at all stages of COVID-19 disease to map the consequences of elevated HA on morbidity and identify the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced HA production. A reduced alveolar surface area was observed in the lungs of deceased COVID-19 patients compared to healthy controls, as visualized by a 3D rendering of lung morphology using light-sheet fluorescence microscopy. We confirmed the presence of HA in lung biopsies and found large quantities of proinflammatory fragmented HA. The association of systemic HA in blood plasma and disease severity was assessed in patients with mild (WHO Clinical Progression Scale, WHO-CPS, 1–5) and severe COVID-19 (WHO-CPS, 6–9) during the acute and convalescent phases and related to lung function. We found that systemic levels of HA were high during acute COVID-19 disease, remained elevated during convalescence, and were associated with a reduced diffusion capacity. In vitro 3D-lung models, differentiated from primary human bronchial epithelial cells, were used to study the effects of SARS-CoV-2 infection on HA metabolism, and transcriptomic analyses revealed a dysregulation of HA synthases and hyaluronidases, both contributing to increased HA in apical secretions. Furthermore, corticosteroid treatment reduced the inflammation and downregulated HA synthases. Our findings demonstrate that HA plays a role in COVID-19 morbidity and that sustained elevated HA concentrations may contribute to long-term respiratory impairment.

Place, publisher, year, edition, pages
American Society for Microbiology, 2024
Keywords
COVID-19, hyaluronan, hyaluronic acid, SARS-CoV-2, lung impairment, 3D-lung model
National Category
Infectious Medicine
Identifiers
urn:nbn:se:umu:diva-229944 (URN)10.1128/mbio.01303-24 (DOI)001318493400001 ()39302125 (PubMedID)2-s2.0-85206959059 (Scopus ID)
Funder
Swedish Heart Lung Foundation, 20200385Swedish Heart Lung Foundation, 20200325Swedish Heart Lung Foundation, 20210078Swedish Heart Lung Foundation, 20200366Swedish Heart Lung Foundation, 20210049The Kempe Foundations, JCK-1827Umeå University, 978018Umeå University, 964781Nyckelfonden, OLL-938628Nyckelfonden, OLL-961416Sjukvårdsregionala forskningsrådet Mellansverige, RFR-968856Sjukvårdsregionala forskningsrådet Mellansverige, RFR-940474Swedish Research Council, 2020-06235Swedish Research Council, 2016-06514Swedish Research Council, 2021-06602Åke Wiberg Foundation, M22-0106Magnus Bergvall Foundation, 2022-186
Available from: 2024-09-23 Created: 2024-09-23 Last updated: 2024-10-28Bibliographically approved
Welén, K., Rosendal, E., Gisslén, M., Lenman, A., Freyhult, E., Fonseca Rodriguez, O., . . . Josefsson, A. (2022). A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. European Urology, 81(3), 285-293
Open this publication in new window or tab >>A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
Show others...
2022 (English)In: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 81, no 3, p. 285-293Article in journal (Refereed) Published
Abstract [en]

Background: Men are more severely affected by COVID-19. Testosterone may influence SARS-CoV-2 infection and the immune response.

Objective: To clinically, epidemiologically, and experimentally evaluate the effect of antiandrogens on SARS-CoV-2 infection.

Designs, settings, and participants: A randomized phase 2 clinical trial (COVIDENZA) enrolled 42 hospitalized COVID-19 patients before safety evaluation. We also conducted a population-based retrospective study of 7894 SARS-CoV-2–positive prostate cancer patients and an experimental study using an air-liquid interface three-dimensional culture model of primary lung cells.

Intervention: In COVIDENZA, patients were randomized 2:1 to 5 d of enzalutamide or standard of care.

Outcome measurements: The primary outcomes in COVIDENZA were the time to mechanical ventilation or discharge from hospital. The population-based study investigated risk of hospitalization, intensive care, and death from COVID-19 after androgen inhibition.

Results and limitations: Enzalutamide-treated patients required longer hospitalization (hazard ratio [HR] for discharge from hospital 0.43, 95% confidence interval [CI] 0.20–0.93) and the trial was terminated early. In the epidemiological study, no preventive effects were observed. The frail population of patients treated with androgen deprivation therapy (ADT) in combination with abiraterone acetate or enzalutamide had a higher risk of dying from COVID-19 (HR 2.51, 95% CI 1.52–4.16). In vitro data showed no effect of enzalutamide on virus replication. The epidemiological study has limitations that include residual confounders.

Conclusions: The results do not support a therapeutic effect of enzalutamide or preventive effects of bicalutamide or ADT in COVID-19. Thus, these antiandrogens should not be used for hospitalized COVID-19 patients or as prevention for COVID-19. Further research on these therapeutics in this setting are not warranted.

Patient summary: We studied whether inhibition of testosterone could diminish COVID-19 symptoms. We found no evidence of an effect in a clinical study or in epidemiological or experimental investigations. We conclude that androgen inhibition should not be used for prevention or treatment of COVID-19.

Place, publisher, year, edition, pages
Elsevier, 2022
Keywords
COVID-19, SARS-CoV-2, Antiandrogen, Randomized trial, Enzalutamide, Bicalutamide, Androgen deprivation therapy
National Category
Cancer and Oncology Public Health, Global Health and Social Medicine Clinical Medicine Infectious Medicine
Identifiers
urn:nbn:se:umu:diva-190911 (URN)10.1016/j.eururo.2021.12.013 (DOI)000809752100020 ()2-s2.0-85122412349 (Scopus ID)
Funder
Knut and Alice Wallenberg Foundation, 2020.0182ProstatacancerförbundetSwedish Cancer Society, 2017/478Swedish Cancer Society, 20 1055 PjFSwedish Heart Lung Foundation, 20200385Region Västerbotten, RV-836351Region Västerbotten, RV-939769
Available from: 2022-01-02 Created: 2022-01-02 Last updated: 2025-02-20Bibliographically approved
Rosendal, E., Mihai, I. S., Becker, M., Das, D., Frängsmyr, L., Persson, B. D., . . . Lenman, A. (2022). Serine protease inhibitors restrict host susceptibility to SARS-CoV-2 infections. mBio, 13(3), Article ID e00892-22.
Open this publication in new window or tab >>Serine protease inhibitors restrict host susceptibility to SARS-CoV-2 infections
Show others...
2022 (English)In: mBio, ISSN 2161-2129, E-ISSN 2150-7511, Vol. 13, no 3, article id e00892-22Article in journal (Refereed) Published
Abstract [en]

The coronavirus disease 2019, COVID-19, is a complex disease with a wide range of symptoms from asymptomatic infections to severe acute respiratory syndrome with lethal outcome. Individual factors such as age, sex, and comorbidities increase the risk for severe infections, but other aspects, such as genetic variations, are also likely to affect the susceptibility to SARS-CoV-2 infection and disease severity. Here, we used a human 3D lung cell model based on primary cells derived from multiple donors to identity host factors that regulate SARS-CoV-2 infection. With a transcriptomics-based approach, we found that less susceptible donors show a higher expression level of serine protease inhibitors SERPINA1, SERPINE1, and SERPINE2, identifying variation in cellular serpin levels as restricting host factors for SARS-CoV-2 infection. We pinpoint their antiviral mechanism of action to inhibition of the cellular serine protease, TMPRSS2, thereby preventing cleavage of the viral spike protein and TMPRSS2-mediated entry into the target cells. By means of single-cell RNA sequencing, we further locate the expression of the individual serpins to basal, ciliated, club, and goblet cells. Our results add to the importance of genetic variations as determinants for SARS-CoV-2 susceptibility and suggest that genetic deficiencies of cellular serpins might represent risk factors for severe COVID-19. Our study further highlights TMPRSS2 as a promising target for antiviral intervention and opens the door for the usage of locally administered serpins as a treatment against COVID-19.

Place, publisher, year, edition, pages
American Society for Microbiology, 2022
Keywords
A1AT, alpha-1-antitrypsin, antithrombin III, ATIII, COVID-19, PAI1, plasminogen activator inhibitor 1, SARS-CoV-2, serpin, TMPRSS2
National Category
Infectious Medicine
Identifiers
urn:nbn:se:umu:diva-203186 (URN)10.1128/mbio.00892-22 (DOI)000797888900001 ()35532162 (PubMedID)2-s2.0-85133144334 (Scopus ID)
Funder
Science for Life Laboratory, SciLifeLabSwedish National Infrastructure for Computing (SNIC), SNIC 2020/6-251Swedish Heart Lung Foundation, 2020038Knut and Alice Wallenberg Foundation, 2020.0182Knut and Alice Wallenberg Foundation, C19R:028Swedish Society for Medical Research (SSMF)The Kempe Foundations, JCK-1827Swedish Research Council, 2016-06598
Available from: 2023-01-17 Created: 2023-01-17 Last updated: 2024-11-01Bibliographically approved
Persson, B. D., Nord, S., Lindquist, R., Danskog, K., Överby, A. K., Kohl, A., . . . Arnberg, N. (2021). BAF45b is required for efficient zika virus infection of HAP1 cells. Viruses, 13(10), Article ID 2007.
Open this publication in new window or tab >>BAF45b is required for efficient zika virus infection of HAP1 cells
Show others...
2021 (English)In: Viruses, E-ISSN 1999-4915, Vol. 13, no 10, article id 2007Article in journal (Refereed) Published
Abstract [en]

The 2016 Zika virus (ZIKV) epidemic illustrates the impact of flaviviruses as emerging human pathogens. For unknown reasons, ZIKV replicates more efficiently in neural progenitor cells (NPCs) than in postmitotic neurons. Here, we identified host factors used by ZIKV using the NCI-60 library of cell lines and COMPARE analysis, and cross-analyzed this library with two other libraries of host factors with importance for ZIKV infection. We identified BAF45b, a subunit of the BAF (Brg1/Brm-associated factors) protein complexes that regulate differentiation of NPCs to post-mitotic neurons. ZIKV (and other flaviviruses) infected HAP1 cells deficient in expression of BAF45b and other BAF subunits less efficiently than wildtype (WT) HAP1 cells. We concluded that subunits of the BAF complex are important for infection of ZIKV and other flavivirus. Given their function in cell and tissue differentiation, such regulators may be important determinants of tropism and pathogenesis of arthropod-borne flaviviruses.

Place, publisher, year, edition, pages
MDPI, 2021
Keywords
BAF45b, DPF1, Flavivirus, Zika virus
National Category
Microbiology in the medical area Infectious Medicine
Identifiers
urn:nbn:se:umu:diva-188850 (URN)10.3390/v13102007 (DOI)000792951900009 ()2-s2.0-85117010328 (Scopus ID)
Funder
EU, Horizon 2020, 734584Swedish Research Council, 2017-02438Swedish Research Council, 2016-00968
Available from: 2021-10-25 Created: 2021-10-25 Last updated: 2025-03-03Bibliographically approved
Zapatero-Belinchón, F. J., Moeller, R., Lasswitz, L., van Ham, M., Becker, M., Brogden, G., . . . Gerold, G. (2021). Fluvastatin mitigates SARS-CoV-2 infection in human lung cells. iScience, 24(12), Article ID 103469.
Open this publication in new window or tab >>Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
Show others...
2021 (English)In: iScience, E-ISSN 2589-0042, Vol. 24, no 12, article id 103469Article in journal (Refereed) Published
Abstract [en]

Clinical data of patients suffering from COVID-19 indicates that statin therapy, used to treat hypercholesterolemia, is associated with a better disease outcome. Whether statins directly affect virus replication or influence the clinical outcome through modulation of immune responses is unknown. We therefore investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that only fluvastatin inhibited low and high pathogenic coronaviruses in vitro and ex vivo in a dose-dependent manner. Quantitative proteomics revealed that fluvastatin and other tested statins modulated the cholesterol synthesis pathway without altering innate antiviral immune responses in infected lung epithelial cells. However, fluvastatin treatment specifically downregulated proteins that modulate protein translation and viral replication. Collectively, these results support the notion that statin therapy poses no additional risk to individuals exposed to SARS-CoV-2 and that fluvastatin has a moderate beneficial effect on SARS-CoV-2 infection of human lung cells.

Place, publisher, year, edition, pages
Elsevier, 2021
Keywords
Drugs, Virology
National Category
Infectious Medicine Clinical Medicine
Identifiers
urn:nbn:se:umu:diva-190104 (URN)10.1016/j.isci.2021.103469 (DOI)000740245300008 ()2-s2.0-85120182160 (Scopus ID)
Funder
Knut and Alice Wallenberg FoundationEU, Horizon 2020, 871029
Available from: 2021-12-10 Created: 2021-12-10 Last updated: 2025-02-18Bibliographically approved
Rajan, A., Palm, E., Trulsson, F., Mundigl, S., Becker, M., Persson, D., . . . Lenman, A. (2021). Heparan Sulfate Is a Cellular Receptor for Enteric Human Adenoviruses. Viruses, 13(2), Article ID 298.
Open this publication in new window or tab >>Heparan Sulfate Is a Cellular Receptor for Enteric Human Adenoviruses
Show others...
2021 (English)In: Viruses, E-ISSN 1999-4915, Vol. 13, no 2, article id 298Article in journal (Refereed) Published
Abstract [en]

Human adenovirus (HAdV)-F40 and -F41 are leading causes of diarrhea and diarrhea-associated mortality in children under the age of five, but the mechanisms by which they infect host cells are poorly understood. HAdVs initiate infection through interactions between the knob domain of the fiber capsid protein and host cell receptors. Unlike most other HAdVs, HAdV-F40 and -F41 possess two different fiber proteins-a long fiber and a short fiber. Whereas the long fiber binds to the Coxsackievirus and adenovirus receptor (CAR), no binding partners have been identified for the short fiber. In this study, we identified heparan sulfate (HS) as an interaction partner for the short fiber of enteric HAdVs. We demonstrate that exposure to acidic pH, which mimics the environment of the stomach, inactivates the interaction of enteric adenovirus with CAR. However, the short fiber:HS interaction is resistant to and even enhanced by acidic pH, which allows attachment to host cells. Our results suggest a switch in receptor usage of enteric HAdVs after exposure to acidic pH and add to the understanding of the function of the short fibers. These results may also be useful for antiviral drug development and the utilization of enteric HAdVs for clinical applications such as vaccine development.

Place, publisher, year, edition, pages
MDPI, 2021
Keywords
capsid proteins, enteric adenovirus, fiber knobs, heparan sulfate, short fibers
National Category
Microbiology in the medical area
Identifiers
urn:nbn:se:umu:diva-181795 (URN)10.3390/v13020298 (DOI)000623302300001 ()2-s2.0-85102606288 (Scopus ID)
Available from: 2021-04-01 Created: 2021-04-01 Last updated: 2024-01-17Bibliographically approved
Arnberg, N. & Lenman, A. (2021). Special issue "adenovirus pathogenesis". Viruses, 13(6), Article ID 1112.
Open this publication in new window or tab >>Special issue "adenovirus pathogenesis"
2021 (English)In: Viruses, E-ISSN 1999-4915, Vol. 13, no 6, article id 1112Article in journal, Editorial material (Other academic) Published
Place, publisher, year, edition, pages
MDPI, 2021
National Category
Microbiology in the medical area
Identifiers
urn:nbn:se:umu:diva-185675 (URN)10.3390/v13061112 (DOI)2-s2.0-85108591525 (Scopus ID)
Available from: 2021-07-02 Created: 2021-07-02 Last updated: 2024-01-17Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0001-5109-9408

Search in DiVA

Show all publications